Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue

Shen,Jiangtao; Du,Xinru; Zhao,Lingxiu; Luo,Hui; Xu,Ziyu

doi:10.3892/ol.2018.8559

Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue

Authors:
- Jiangtao Shen
- Xinru Du
- Lingxiu Zhao
- Hui Luo
- Ziyu Xu
View Affiliations

Affiliations: Department of Orthopedics, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China, Department of Orthopedics, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Medical Information Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: April 24, 2018 https://doi.org/10.3892/ol.2018.8559
Pages: 10017-10025

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present retrospective study was designed to compare the pain relief, surgery duration, life quality, survival time and relative prognostic factors in multiple myeloma (MM) bone disease patients with different surgical sites. A total of 65 cases were enrolled and divided into two groups. Group A included patients with lesions located in the spine, while Group B included patients with lesions located in the long bone or soft tissue. Pain relief was measured by the visual analogue scale (VAS), neurological impairment was determined according to Frankel classification, and survival was assessed by the Kaplan‑Meier method. Cox regression analysis was also used to estimate the effect of factors on the prediction of survival. The hospitalization time, preoperative duration of symptoms, method of surgery, complications, recurrence and survival time were evaluated and compared retrospectively. Pain relief and improvement of life quality were observed in all the patients in groups A and B. No significant differences were detected for the majority of parameters compared between groups A and B, with the exception of the surgery duration, as well as the postoperative VAS score at 1 and 6 months after surgery. The multivariate Cox regression analysis revealed several risk factors significantly associated with survival, including the preoperative VAS score, postoperative chemotherapy, prothrombin time activity (PTA), albumin, lactate dehydrogenase and urine protein level. In conclusion, surgical treatment was an effective therapeutic method in patients with MM. Postoperative analgesic use should be individualized according to the different surgical sites and postoperative periods. Furthermore, preoperative pain, PTA, albumin, urine protein level and postoperative chemotherapy are associated with prognosis.

View Figures

View References

1	Terpos E, Berenson J, Raje N and Roodman GD: Management of bone disease in multiple myeloma. Expert Rev Hematol. 7:113–125. 2014. View Article : Google Scholar : PubMed/NCBI
2	Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B and Mundy GR: Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 111:2833–2842. 2008. View Article : Google Scholar : PubMed/NCBI
3	Raje N and Roodman GD: Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 17:1278–1286. 2011. View Article : Google Scholar : PubMed/NCBI
4	Terpos E and Dimopoulos MA: Myeloma bone disease: Pathophysiology and management. Ann Oncol. 16:1223–1231. 2005. View Article : Google Scholar : PubMed/NCBI
5	Vallet S and Anderson KC: CCR1 as a target for multiple myeloma. Expert Opin Ther Targets. 15:1037–1047. 2011. View Article : Google Scholar : PubMed/NCBI
6	Coleman RE: Bisphosphonates: Clinical experience. Oncologist. 9 Suppl 4:S14–S27. 2004. View Article : Google Scholar
7	Terpos E, Cibeira MT, Blade J and Ludwig H: Management of complications in multiple myeloma. Semin Hematol. 46:176–189. 2009. View Article : Google Scholar : PubMed/NCBI
8	Adamietz IA, Schöber C, Schulte RW, Peest D and Renner K: Palliative radiotherapy in plasma cell myeloma. Radiother Oncol. 20:111–116. 1991. View Article : Google Scholar : PubMed/NCBI
9	Greipp PR, Miguel San J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
10	Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
11	Dimopoulos MA and Terpos E: Multiple myeloma. Ann Eur Soc Med Oncol. 21 Suppl 7:vii143–vii150. 2010.
12	He J, Yang L, Han X, Zheng G, Zheng W, Wei G, Wu W, Ye X, Shi J, Xie W, et al: The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. PLoS One. 9:e991742014. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Wang L, Lu Y, Chen X, Geng Q, Wang W and Xia Z: Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients. Onco Targets Ther. 9:587–595. 2016.PubMed/NCBI
14	Zham H, Moradi A, Rakhshan A, Zali A, Rahbari A, Raee M, Ashrafi F, Ahadi M, Larijani L, Baikpour M and Khayamzadeh M: Does Histologic Subtype Influence the Post-Operative Outcome in Spinal Meningioma? Iran J Cancer Prev. 9:e38382016.PubMed/NCBI
15	Yasuda T, Kawaguchi Y, Suzuki K, Nakano M, Seki S, Watabnabe K, Kanamori M and Kimura T: Five-year follow up results of posterior decompression and fixation surgery for delayed neural disorder associated with osteoporotic vertebral fracture. Medicine (Baltimore). 96:e93952017. View Article : Google Scholar : PubMed/NCBI
16	Weinstein JN and McLain RF: Primary tumors of the spine. Spine (Phila Pa 1976). 12:843–851. 1987. View Article : Google Scholar : PubMed/NCBI
17	Ha KY, Min CK, Seo JY, Kim YH, Ahn JH, Hyun NM and Kim YC: Bone cement augmentation procedures for spinal pathologic fractures by multiple myeloma. J Korean Med Sci. 30:88–94. 2015. View Article : Google Scholar : PubMed/NCBI
18	Rades D, Huttenlocher S, Dunst J, Bajrovic A, Karstens JH, Rudat V and Schild SE: Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol. 28:3597–3604. 2010. View Article : Google Scholar : PubMed/NCBI
19	Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, et al: Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol. 12:743–752. 2011. View Article : Google Scholar : PubMed/NCBI
20	Khan OA, Brinjikji W and Kallmes DF: Vertebral augmentation in patients with multiple myeloma: A pooled analysis of published case series. AJNR Am J Neuroradiol. 35:207–210. 2014. View Article : Google Scholar : PubMed/NCBI
21	Edwards CM, Zhuang J and Mundy GR: The pathogenesis of the bone disease of multiple myeloma. Bone. 42:1007–1013. 2008. View Article : Google Scholar : PubMed/NCBI
22	Weber MH, Burch S, Buckley J, Schmidt MH, Fehlings MG, Vrionis FD and Fisher CG: Instability and impending instability of the thoracolumbar spine in patients with spinal metastases: A systematic review. Int J Oncol. 38:5–12. 2011.PubMed/NCBI
23	Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, Harrop JS, Fehlings MG, Boriani S, Chou D, et al: A novel classification system for spinal instability in neoplastic disease: An evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 35:E1221–E1229. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zeifang F, Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Bernd L and Sabo D: Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol J Eur Soc Med Oncol. 16:222–227. 2005. View Article : Google Scholar
25	Hannisdal E, Kildahl-Andersen O, Grøttum KA and Lamvik J: Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol. 45:198–202. 1990. View Article : Google Scholar : PubMed/NCBI
26	Cerny J, Fadare O, Hutchinson L and Wang SA: Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 81:65–69. 2008. View Article : Google Scholar : PubMed/NCBI
27	Köse M, Buraniqi E, Akpinar TS, Kayacan SM and Tükek T: Relapse of multiple myeloma presenting as extramedullary plasmacytomas in multiple organs. Case Rep Hematol. 2015:4523052015.PubMed/NCBI
28	Lahtinen R, Laakso M, Palva I, Virkkunen P and Elomaa I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet (London, England). 340:1049–1052. 1992. View Article : Google Scholar : PubMed/NCBI
29	Tatsui H, Onomura T, Morishita S, Oketa M and Inoue T: Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine. 21:2143–2148. 1996. View Article : Google Scholar : PubMed/NCBI
30	Zadnik PL, Goodwin GC, Karami KJ, Mehta AI, Amin AG, Groves ML, Wolinsky JP, Witham TF, Bydon A, Gokaslan ZL and Sciubba DM: Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. J Neurosurg Spine. 22:301–309. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zou J, Mei X, Gan M and Yang H: Kyphoplasty for spinal fractures from multiple myeloma. J Surg Oncol. 102:43–47. 2010. View Article : Google Scholar : PubMed/NCBI
32	Kasperk C, Haas A, Hillengass J, Weiss C, Neben K, Goldschmidt H, Sommer U, Nawroth P, Meeder PJ, Wiedenhöfer B, et al: Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study. J Surg Oncol. 105:679–686. 2012. View Article : Google Scholar : PubMed/NCBI
33	Harrington KD: Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy. Clin Orthop Relat Res. 177–197. 1988.PubMed/NCBI
34	Kluger P, Korge A and Scharf HP: Strategy for the treatment of patients with spinal neoplasms. Spinal Cord. 35:429–436. 1997. View Article : Google Scholar : PubMed/NCBI
35	Helweg-Larsen S: Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand. 94:269–275. 1996. View Article : Google Scholar : PubMed/NCBI
36	Pascal-Moussellard H, Broc G, Pointillart V, Siméon F, Vital JM and Sénégas J: Complications of vertebral metastasis surgery. Eur Spine J. 7:438–444. 1998. View Article : Google Scholar : PubMed/NCBI
37	Jansson KA and Bauer HC: Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases. Eur Spine J. 15:196–202. 2006. View Article : Google Scholar : PubMed/NCBI
38	Weigel B, Maghsudi M, Neumann C, Kretschmer R, Muller FJ and Nerlich M: Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine. 24:2240–2246. 1999. View Article : Google Scholar : PubMed/NCBI
39	Lau D, Leach MR, La Marca F and Park P: Independent predictors of survival and the impact of repeat surgery in patients undergoing surgical treatment of spinal metastasis. J Neurosurg Spine. 17:565–576. 2012. View Article : Google Scholar : PubMed/NCBI
40	Terpos E, Dimopoulos MA and Moulopoulos LA: The Role of Imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. Meeting. 35:e407–e417. 2016.
41	Rajkumar SV: Myeloma today: Disease definitions and treatment advances. Am J Hematol. 91:90–100. 2016. View Article : Google Scholar : PubMed/NCBI
42	Long SF, Chen GA and Fang MS: Levels of interleukin-16 in peripheral blood of 52 patients with multiple myeloma and its clinical significance. Int J Clin Exp Med. 8:22520–22524. 2015.PubMed/NCBI
43	Bataille R, Boccadoro M, Klein B, Durie B and Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 80:733–737. 1992.PubMed/NCBI
44	Kariyawasan CC, Hughes DA, Jayatillake MM and Mehta AB: Multiple myeloma: Causes and consequences of delay in diagnosis. QJM. 100:635–640. 2007. View Article : Google Scholar : PubMed/NCBI
45	Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E and Roman E: Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: A report from the Haematological Malignancy Research Network. BMC Hematol. 13:92013. View Article : Google Scholar : PubMed/NCBI